Chemomab Therapeutics (NASDAQ:CMMB) Stock Price Down 3.8% – Time to Sell?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB)’s share price dropped 3.8% during trading on Wednesday . The stock traded as low as $1.23 and last traded at $1.26. Approximately 118,229 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 194,593 shares. The stock had previously closed at $1.31.

Chemomab Therapeutics Stock Performance

The business’s 50 day moving average is $1.56 and its 200 day moving average is $1.16. The company has a market capitalization of $13.92 million, a price-to-earnings ratio of -0.79 and a beta of 0.52.

Chemomab Therapeutics (NASDAQ:CMMB) last released its earnings results on Wednesday, August 21st. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). During the same period in the previous year, the business earned ($0.72) earnings per share. Sell-side analysts predict that Chemomab Therapeutics Ltd. will post -1 EPS for the current year.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).